BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8640675)

  • 1. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
    Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
    Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
    Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
    Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
    Cuatrecasas M; Catasus L; Palacios J; Prat J
    Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
    Kuwata T; Kitagawa M; Takemura T; Hirokawa K
    Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
    Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
    Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
    Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
    Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
    Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
    Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
    J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.
    Yamashita H; Murakami N; Asari T; Okuma K; Ohtomo K; Nakagawa K
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1165-72. PubMed ID: 19101092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
    Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
    Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
    Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
    Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
    Zheng W; Luo MP; Welt C; Lambert-Messerlian G; Sung CJ; Zhang Z; Ying SY; Schneyer AL; Lauchlan SC; Felix JC
    Gynecol Oncol; 1998 Apr; 69(1):23-31. PubMed ID: 9570994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.